Want to see SERA full AI Analyst Report?
SERA Stock Chart & Stats
$2.05
-$0.12(-5.53%)
At close: 4:00 PM EDT
$2.05
-$0.12(-5.53%)
Day’s Range― - ―
52-Week Range$1.56 - $3.95
Previous Close$2.05
Volume18.94K
Average Volume (3M)40.22K
Market Cap
$78.71M
Enterprise Value$57.13
Total Cash (Recent Filing)$47.40M
Total Debt (Recent Filing)$2.50M
Price to Earnings (P/E)―
Beta1.37
Next Earnings
Nov 11, 2026EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.65
Shares Outstanding38,190,968
10 Day Avg. Volume55,279
30 Day Avg. Volume40,220
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)1.86
Price to Sales (P/S)1735.84
P/FCF Ratio-5.34
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$6.00Price Target Upside192.68% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.66
Revenue Forecast (FY)$361.50K
Bulls Say, Bears Say
Bulls Say
Cash Runway & Cost ReductionA sizable cash balance coupled with a clear plan to cut ~ $10M in annual operating expenses materially extends the company's runway through 2029. This reduces near-term dilution risk and provides time to execute commercialization, pursue payer decisions, and reach scalable volumes before requiring additional capital.
Commercial & Payer MomentumGrowing partner programs, increasing provider reach and active engagement with multiple payers indicate structural progress in go-to-market and reimbursement outreach. These moves build distribution, payer relationships and scaleable referral pathways that can sustain revenue growth once coverage and adoption broaden.
Board Commercial ExpertiseBringing a veteran diagnostics commercial executive to the board strengthens governance and operational oversight during a commercialization pivot. Experienced leadership can improve payer negotiation, scaling of commercial teams, and execution discipline—durable factors that support longer-term adoption and market access.
Bears Say
Very Weak Revenue & MarginsRevenue levels are tiny and declining while gross profit is negative, indicating the company currently loses money on sales at scale. Persistent negative unit economics and low volumes mean the business must materially improve reimbursement, pricing or scale to achieve sustainable margins and profitability.
Persistent Cash BurnConsistent negative operating and free cash flows show the business consumes cash to fund operations. Even with current runway, ongoing burn makes the company vulnerable if commercialization or payer wins slip, raising the likelihood of future capital raises that could dilute shareholders or constrain execution.
Slow Payer/adoption TimelinesReimbursement and adoption cycles are lengthy—Medicaid pilot outcomes and state coverage decisions can take ~2 years. Such structural timing delays postpone scalable revenue, extend dependency on cash reserves, and increase execution risk if payer or provider uptake lags expectations.
Sera Prognostics News
SERA FAQ
What was Sera Prognostics’s price range in the past 12 months?
Sera Prognostics lowest stock price was $1.56 and its highest was $3.95 in the past 12 months.
What is Sera Prognostics’s market cap?
Sera Prognostics’s market cap is $78.71M.
When is Sera Prognostics’s upcoming earnings report date?
Sera Prognostics’s upcoming earnings report date is Nov 11, 2026 which is in 90 days.
How were Sera Prognostics’s earnings last quarter?
Sera Prognostics released its earnings results on Aug 12, 2026. The company reported -$0.18 earnings per share for the quarter, missing the consensus estimate of -$0.154 by -$0.026.
Is Sera Prognostics overvalued?
According to Wall Street analysts Sera Prognostics’s price is currently Undervalued.
Does Sera Prognostics pay dividends?
Sera Prognostics does not currently pay dividends.
What is Sera Prognostics’s EPS estimate?
Sera Prognostics’s EPS estimate is -0.16.
How many shares outstanding does Sera Prognostics have?
Sera Prognostics has 38,190,968 shares outstanding.
What happened to Sera Prognostics’s price movement after its last earnings report?
Sera Prognostics reported an EPS of -$0.18 in its last earnings report, missing expectations of -$0.154. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Sera Prognostics?
Currently, no hedge funds are holding shares in SERA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sera Prognostics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.00 (192.68% Upside)
$6.00 (192.68% Upside)
Blogger Sentiment
Neutral
SERA Sentiment 100%
Sector Average 61%
Sector Average 61%
Insider Transactions
Sold Shares
Worth $87.3K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-58.89%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-20.85%
Trailing 12-Months
Company Description
Sera Prognostics
Sera Prognostics, Inc. is a women's health diagnostics firm that focuses on creating, advancing, and bringing to market biomarker tests aimed at improving pregnancy results. Their primary product, the PreTRM test, is a blood-based biomarker assay specifically designed to predict the likelihood of spontaneous preterm birth in singleton pregnancies where no symptoms are yet present. Additionally, the company is cultivating a portfolio of potential tests for various other pregnancy-related conditions, such as preeclampsia, predicting time-to-birth at a molecular level, gestational diabetes mellitus, restricted fetal growth, stillbirth, and postpartum depression. Established in 2008, the organization's main operations are based in Salt Lake City, Utah.
SERA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mixed picture: strong strategic progress on commercialization, payer engagement, media awareness, scientific publications and a clear plan to reduce operating expense that together support a multi-year commercial opportunity. However, near-term financials remain weak — Q1 revenue fell to $14k (down ~63% YoY), a continuing net loss (~$8.4M) and management expects 2026 revenue to be modest and uneven while payer coverage and broader adoption timelines play out. Given meaningful operational and evidence milestones but limited near-term revenue visibility, the tone is cautiously constructive but balanced by financial and timing risks.View all SERA earnings summariesSERA Stock 12 Month Forecast
Average Price Target
$6.00
▲(192.68% Upside)
Technical Analysis
Ownership Overview
5.29% Insiders
4.07% Mutual Funds
0.70% Other Institutional Investors
86.19% Public Companies and
Individual Investors